Catheter Ablation for Atrial Fibrillation in Non-Fluoroscopic Lab (NCT06719921) | Clinical Trial Compass
By InvitationNot Applicable
Catheter Ablation for Atrial Fibrillation in Non-Fluoroscopic Lab
China724 participantsStarted 2025-04-22
Plain-language summary
This randomized controlled trial investigates the efficacy and safety of atrial fibrillation (AF) catheter ablation performed in non-fluoroscopic electrophysiology (EP) labs compared to conventional fluoroscopic digital subtraction angiography labs. The trial hypothesizes non-inferiority in outcomes, with the added benefits of simplified lab environment. Up to 724 participants aged 18-80 with paroxysmal or persistent AF will be enrolled across 10 centers. Participants will be randomized (1:1) to undergo catheter ablation in non-fluoroscopic or fluoroscopic labs, using pulmonary vein isolation (PVI) as the primary ablation strategy. The primary endpoints are freedom from AF recurrence at 12 months and composite safety outcomes related to procedure. Secondary endpoints mainly include procedure duration, recurrence during the initial 90 days, incidence of peri-procedural complications and changes in quality-of-life forms.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age: ≥18 years
✓. Patients diagnosed with paroxysmal AF or persistent AF with a duration of 1 years or less, who are referred for catheter ablation.
✓. Patients referred for catheter ablation as a first-time intervention (no prior catheter ablation or surgical procedures for AF).
✓. The patient is able and willing to provide written informed consent.
Exclusion criteria
✕. Patients with contraindication to anticoagulation
✕. Patients with contraindication to right or left sided cardiac catheterization
✕. X-ray fluoroscopy is required in the procedure, such as ablation combined with VOM ethanol ablation, epicardial ablation, LAAO, CAG, etc.
✕. Serious known concomitant disease with a life expectancy of \< 1 year
✕. MI, CABG, or PCI within the preceding 3 months
✕
What they're measuring
1
Freedom from Documented AF Without Antiarrhythmic Drugs at 12 Months Post-Ablation
Timeframe: From enrollment to the end of treatment at 12 months
2
Incidence of Composite Procedure-Related Serious Adverse Events at 3 Months Post-Ablation
Timeframe: From enrollment to the end of treatment at 3 months